Health. Quality. Life.

EXTRAORDINARY INFORMATION

On the opinion of the Board of Directors regarding the voluntary public purchase offer of Servier Group

Egis Pharmaceuticals PLC (Egis) announces that the Board of Directors of Egis has held a meeting which was to discuss and vote on the opinion concerning the voluntary public purchase offer (Offer) made by Arts et Techniques du Progrès, a wholly owned subsidiary of Servier Group.

The opinion of the Board of Directors related to the Offer is attached hereto.

Budapest, October 1, 2013

Egis Pharmaceuticals PLC

Egis Pharmaceuticals PLC
H-1106 Budapest, Keresztúri út 30-38.
Postal address: H-1475 Budapest 10 P.O. Box 100
Phone: +36-1-803-5555, Fax: +36-1-803-5529
Metropolitan Court of Budapest: 01-10-041762

Health. Quality. Life.

OPINION OF THE BOARD OF DIRECTORS
of
EGIS PHARMACEUTICALS Plc.
Registered seat: 1106 Budapest, Keresztúri út 30-38., Hungary

This opinion of the Board of Directors of Egis Pharmaceuticals Plc. ("**Company**") adopted on October 1st, 2013 is established in connection with the voluntary public purchase offer ("**Offer**") made by Arts et Techniques du Progrès (registered seat: 25 rue Eugène Vignat, 45000 Orléans, France) ("**Offeror**") relating to 49,09% of the registered shares of the Company corresponding to 3,821,793 shares and approved by the Hungarian Financial Supervisory Authority by its resolution of 27 September 2013. Hungarian law does not require the creation of a special committee of the Board of Directors to consider the Offer, therefore, no such committee was created. The position with respect to the Offer was considered by the full Board of Directors of the Company under Hungarian law.

1. First, the Board of Directors wishes to emphasize that as a matter of Hungarian law, the Board of Directors shall at all times act in a manner that the interests of the Company are granted priority. With respect to the above statutory obligation of the Board of Directors, its primary objective was to consider and evaluate the Offer from this perspective.

In order to consider and evaluate the Offer from the above perspective, the Board of Directors has studied the Offer, as well as the operation plan regarding the future operation of the Company ("**Operation Plan**") and the business report on the economic activities of the Offeror ("**Business Report**") prepared by the Offeror.

(i) The Offeror, a wholly owned subsidiary of Servier Monde, controlled as at 30 September 2012, 23 subsidiaries (including the Company) and held participations in 7 other entities of Servier Group.

Servier Group is the first French private and independent pharmaceutical group and has grown through international expansion, research and development of innovative medicines and acquisitions, increasing its scale and product offering gradually.

(ii) The Servier Group's generic business is handled by three affiliates, one of them being the Company, in which the Offeror has held 50,91% of the shares since 1995.

(iii) The Offeror declared that it would keep the Company's own name, identity and business strategy to further develop the Company's market positions either through

Egis Pharmaceuticals PLC
H-1106 Budapest, Keresztúri út 30-38.
Postal address: H-1475 Budapest 10 P.O. Box 100
Phone: +36-1-803-5555, Fax: +36-1-803-5529
Metropolitan Court of Budapest: 01-10-041762

organic growth or through acquisitions or geographical expansion, as the case may be, depending on market conditions.

(iv) Pursuant to the declaration made by the Offeror, organic growth paths of the Company will include the continued research and development activities to renew and expand the generic products portfolio of the Company, investments in the development and renewal of the active pharmaceutical ingredients and finished pharmaceutical production capacities of the Company in Hungary as well as the end stage production, distribution and promotion of biosimilar medical products by the Company. Pursuant to the Offeror such developments should further enhance the export activities of the Company from Hungary. Offeror also plans that the Company should further develop its presence on its current markets, including Hungary, by entering new pharmaceutical market segments.

(v) Pursuant to Offeror, possible future acquisitions by the Company may target entering new markets or strengthening the presence in those countries where the Company may expect attractive growth rates and profitability. As already planned and communicated by the Company, these possible acquisitions and other type of investments will continue to be funded by the profits created by the Company.

(vi) The Offeror wishes to continue to rely on the expertise and experience of the Company's employees to be able to accomplish its business strategy regarding the Company detailed in the Operation Plan and Business Report, and so that the Company can remain successful on its markets and can enter new markets to further enforce the Company's market share. In accordance with the above, the Offeror, based on its declaration, wishes to keep the Company's own name, identity and business strategy following the acquisition of all shares in the Company and it does not wish to introduce fundamental amendments in the field of the employment as a consequence of the Offer.

(vii) The Offeror confirmed its intention to rely upon the executive management and other key elements of the current corporate management structure and confirmed that the Offer is not expected to have any direct consequence in that regard. If the Company became a private company limited by shares, in order to comply with the applicable regulations, the Offeror may decide to modify the composition of the corporate bodies of the Company but the Offeror has already expressed its intention to maintain the Supervisory Board as well as the ratio of employees' representatives in the Supervisory Board.

Based on the above considerations, the Board of Directors is confident that it can continue to implement its current strategy – already communicated to the shareholders – with the strong support of the majority shareholder, who has held its majority participation for 18 years. The Board of Directors is of the opinion that – with regard to the considerable market share, role and expertise of Servier Group in the national and international markets – the above objectives of the Offeror in connection with the Company are reasonable and are likely to be achieved.

2. Second, the Board of Directors wishes to point out that its statutory obligation to give priority to the interests of the Company does not preclude it from evaluating the Offer also from the perspective of the shareholders. The Board of Directors has reviewed the Offer from this perspective and hereby wishes to share its considerations with the shareholders. In this regard, however, attention of the shareholders is explicitly drawn to the fact that the Board of Directors – when considering the Offer from a shareholders' perspective – could not consider all possible aspects and individual shareholders may have other or further considerations (such as e.g. taxation, social security, exchange rate risk or various other financial considerations). Therefore, attention of the shareholders is explicitly drawn to the fact that the decision to accept or refuse the Offer shall vest in each individual shareholder based on its own or its advisors' analysis of the Offer. The main consideration aspects of the Board of Directors are as follows.

(i) One of the fundamental elements of an offer – such as the Offer – is the purchase price offered in exchange for the shares. The purchase price per share offered by the Offeror is HUF 28,000 (that is twenty eight thousand Hungarian Forint) (the "**Offer Price**"), payable by the Offeror to the shareholders validly accepting the Offer, in Hungarian Forints, by way of wire transfer, no later than 5 (five) business days after the closing day of the Offer.

(ii) The determination of the Offer Price is in accordance with the method of calculation provided for in the statutory provisions of the Hungarian Capital Markets Act. Furthermore, the Offer Price goes beyond the requirements:

The Offer Price represents a premium of 33% over the closing price of the shares on the Budapest Stock Exchange on 23 September 2013, the last trading day preceding the announcement of the Offer and a premium of 38% over the average stock exchange price of the shares weighted by the volume of trade over the six months preceding 23 September 2013.

The Offer Price represents a premium of more than 21% over the 30 September 2012 IFRS-based, consolidated, audited equity per share value of the Company.

(iii) The Board of Directors wishes to point out that the above quoted closing price and average trading price information reflected the evaluation of the Company's shares by the market following a significant growth of the trading price over the few months preceding the announcement of the Offer.

(iv) According to the statutory provisions of the Hungarian Capital Markets Act in case of a voluntary public purchase offer, such as the Offer, a counteroffer cannot be made.

(v) The Offeror has indicated in substance that, irrespective of the actual result of the Offer, it may propose to the general meeting of the Company to delist the Company's shares from the Budapest Stock Exchange after the completion of the Offer. As mentioned by the Offeror, should the Company's shares be delisted, the shares would not have a formal trading platform and the ability of the shareholders to sell their shares would be substantially limited.

3. Based on the above the Board of Directors is of the opinion that the Offer can be considered to be fair for the Company and for a significant number of shareholders.

The foregoing constitutes the Board of Directors' statement and recommendation with respect to the Offer.

In representation of the Board of Directors of Egis Pharmaceuticals Plc.:

Signatures:

Dr Jean-Philippe Seta

Chairman of the Board of Directors

Dr István Hodász

Chief Executive Officer